1 reports of this reaction
3.6% of all GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 reports
#4 most reported adverse reaction
ASTHENOPIA is the #4 most commonly reported adverse reaction for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400, manufactured by CVS Pharmacy. There are 1 FDA adverse event reports linking GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 to ASTHENOPIA. This represents approximately 3.6% of all 28 adverse event reports for this drug.
Patients taking GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 who experience asthenopia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENOPIA is moderately reported among GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 users, representing a notable but not dominant share of adverse events.
In addition to asthenopia, the following adverse reactions have been reported for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400:
The following drugs have also been linked to asthenopia in FDA adverse event reports:
ASTHENOPIA has been reported as an adverse event in 1 FDA reports for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENOPIA accounts for approximately 3.6% of all adverse event reports for GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400, making it a notable side effect.
If you experience asthenopia while taking GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.